Hematological Malignancies Program and Center for Precision Medicine in Leukemia.
Department of Pharmaceutical Sciences.
Blood Adv. 2022 Jun 14;6(11):3386-3397. doi: 10.1182/bloodadvances.2022006965.
Understanding the genomic and epigenetic mechanisms of drug resistance in pediatric acute lymphoblastic leukemia (ALL) is critical for further improvements in treatment outcomes. The role of transcriptomic response in conferring resistance to l-asparaginase (LASP) is poorly understood beyond asparagine synthetase (ASNS). We defined reproducible LASP response genes in LASP-resistant and LASP-sensitive ALL cell lines as well as primary leukemia samples from newly diagnosed patients. Defining target genes of the amino acid stress response-related transcription factor activating transcription factor 4 (ATF4) in ALL cell lines using chromatin immunoprecipitation sequencing (ChIP-seq) revealed 45% of genes that changed expression after LASP treatment were direct targets of the ATF4 transcription factor, and 34% of these genes harbored LASP-responsive ATF4 promoter binding events. SLC7A11 was found to be a response gene in cell lines and patient samples as well as a direct target of ATF4. SLC7A11 was also one of only 2.4% of LASP response genes with basal level gene expression that also correlated with LASP ex vivo resistance in primary leukemia cells. Experiments using chemical inhibition of SLC7A11 with sulfasalazine, gene overexpression, and partial gene knockout recapitulated LASP resistance or sensitivity in ALL cell lines. These findings show the importance of assessing changes in gene expression following treatment with an antileukemic agent for its association with drug resistance and highlight that many response genes may not differ in their basal expression in drug-resistant leukemia cells.
了解儿童急性淋巴细胞白血病 (ALL) 中耐药的基因组和表观遗传机制对于进一步提高治疗效果至关重要。除天冬酰胺合成酶 (ASNS) 外,转录组反应在赋予对 L-天冬酰胺酶 (LASP) 耐药性方面的作用还知之甚少。我们在 LASP 耐药和 LASP 敏感的 ALL 细胞系以及新诊断患者的原始白血病样本中定义了可重复的 LASP 反应基因。使用染色质免疫沉淀测序 (ChIP-seq) 在 ALL 细胞系中定义与氨基酸应激反应相关转录因子激活转录因子 4 (ATF4) 的靶基因,发现 LASP 处理后表达发生变化的基因中有 45%是 ATF4 转录因子的直接靶基因,其中 34%的基因具有 LASP 反应性 ATF4 启动子结合事件。SLC7A11 被发现是细胞系和患者样本中的反应基因,也是 ATF4 的直接靶基因。SLC7A11 也是仅有的 2.4% 的 LASP 反应基因之一,其基础水平基因表达与初级白血病细胞中的 LASP 体外耐药性相关。使用柳氮磺胺吡啶等化学抑制 SLC7A11、基因过表达和部分基因敲除的实验在 ALL 细胞系中再现了 LASP 耐药或敏感。这些发现表明,评估抗白血病药物治疗后基因表达的变化对于与耐药性相关非常重要,并强调许多反应基因在耐药性白血病细胞中的基础表达可能没有差异。